Incyte (NASDAQ:INCY) issued its earnings results on Thursday. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.54, Morningstar.com reports. The firm had revenue of $444.20 million during the quarter, compared to analyst estimates of $435.23 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The business’s revenue was up 36.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.05 earnings per share.
Shares of Incyte (NASDAQ:INCY) traded up $0.44 during trading on Friday, reaching $86.03. 2,470,000 shares of the company’s stock were exchanged, compared to its average volume of 1,890,000. The company has a market capitalization of $18,160.00, a P/E ratio of -55.15 and a beta of 0.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. Incyte has a fifty-two week low of $80.85 and a fifty-two week high of $153.15.
A number of brokerages have recently issued reports on INCY. Oppenheimer reissued a “hold” rating and set a $110.00 target price (down from $120.00) on shares of Incyte in a research note on Monday, January 22nd. Raymond James Financial reissued a “buy” rating on shares of Incyte in a research note on Tuesday, December 12th. BidaskClub raised shares of Incyte from a “strong sell” rating to a “sell” rating in a research note on Friday, January 26th. Zacks Investment Research lowered shares of Incyte from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Finally, ValuEngine lowered shares of Incyte from a “hold” rating to a “sell” rating in a research note on Wednesday, November 29th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Incyte presently has an average rating of “Buy” and a consensus target price of $142.94.
A number of institutional investors have recently made changes to their positions in INCY. Financial Gravity Companies Inc. bought a new position in Incyte in the fourth quarter worth about $120,000. Advantage Investment Management LLC grew its stake in shares of Incyte by 1,233.3% during the fourth quarter. Advantage Investment Management LLC now owns 2,000 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1,850 shares during the last quarter. Private Advisor Group LLC purchased a new stake in shares of Incyte during the third quarter worth about $203,000. Mission Wealth Management LP purchased a new stake in shares of Incyte during the fourth quarter worth about $213,000. Finally, Westover Capital Advisors LLC purchased a new stake in shares of Incyte during the fourth quarter worth about $228,000. Institutional investors and hedge funds own 90.02% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/15/incyte-incy-releases-quarterly-earnings-results-beats-estimates-by-0-54-eps.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.